Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2269557 for acute exacerbation of COPD
NL-OMON43618Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GSK2269557 + standard of care with Placebo + standard of care (2 arms). Primary endpoints: siVaw at FRC after 12 days, siVaw at TLC after 12 days and 2 more. Started May 2015; status: active, not recruiting.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON43618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43618.